Shortly after the revised TNI Law was passed, the territorial structure was expanded. The number of regional military ...

Discover the leading mobile application testing tools for DevOps teams in 2025, aimed at enhancing performance, stability, and agile release cycles for businesses worldwide.

MORE than 30 years after East 17 bagged the Christmas No1 with Stay Another Day, musician Tony Mortimer continues to rake in thousands from the track every year. As the songwriter, Tony – not the band ...

There's a case to be made that Indiana Fever superstar Caitlin Clark's No. 22 is the most recognizable number in women's sports right now. This is largely owed to Clark being arguably the biggest star ...

The US Navy’s beleaguered shipbuilding program took a major hit on Tuesday as Navy Secretary John Phelan announced he was cancelling plans to buy Constellation-class frigates, once heralded as a key ...

About 87 percent of Americans graduate with a high school diploma. For the other 13 percent, dropping out often seems like that’s the only option. For Delana Wilson, 34, her childhood in Augusta, ...

Minnesota officials have suspended payments to providers of another Medicaid-funded program, citing “credible allegations of fraud” as they attempt to crack down on schemes to swindle state and ...

Milwaukee County is using grant money to continue its Courthouse Navigator Program after federal funding was cut. The program, which helps people navigate the court system, lost its AmeriCorps funding ...

Green Bay Packers new star Micah Parsons wanted to keep his No. 11 jersey, but the NFL’s steep financial demands forced his hand to change it. Micah Parsons is about to begin a new chapter in his ...

The Java ecosystem has historically been blessed with great IDEs to work with, including NetBeans, Eclipse and IntelliJ from JetBrains. However, in recent years Microsoft's Visual Studio Code editor ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition. Pfizer's last remaining GLP-1 agonist, ...